Direct Purchaser Class Certified in Zetia MDL


Bradley J. Demuth Bradley J. Demuth
Partner

Tel: (212) 983-9330
Fax: (212) 983-9331
E-mail: bdemuth@faruqilaw.com

In an order entered on August 21, 2020 in the Zetia (Ezetimibe) Antitrust Litigation MDL, Senior United States District Judge Rebecca Beach Smith overruled Defendants’ objections and adopted and approved in full United States Magistrate Judge Douglas E. Miller’s prior Report and Recommendation proposing to certify a 35-member class of Zetia direct purchasers.  

Zetia is a brand pharmaceutical drug indicated to reduce blood cholesterol levels marketed in the United States by Merck & Co., Inc.  Plaintiffs in the MDL allege that Merck conspired with its ostensible generic competitors Glenmark Pharmaceuticals Inc., USA to forestall generic competition and thereby preserve billions of dollars in annual Zetia brand sales for several years.

Faruqi and Faruqi, LLP is one of the leading firms representing the direct purchaser class plaintiffs in the MDL.
 

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Delaware

3828 Kennett Pike Suite 201
Wilmington, Delaware 19807
(302) 482-3182
(302) 482-3612

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Wilmington, Delaware

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania